MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

BIND Therapeutics Company Profile (NASDAQ:BIND)

Consensus Ratings for BIND Therapeutics (NASDAQ:BIND) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $12.33 (178.40% upside)

Analysts' Ratings History for BIND Therapeutics (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetActions
4/7/2015OppenheimerInitiated CoverageOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Stifel NicolausLower Price TargetBuy$20.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Credit SuisseDowngradeOutperform -> Neutral$20.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2014Stifel NicolausInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/3/2014Credit SuisseReiterated RatingOutperform$21.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2013Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2013JMP SecuritiesInitiated CoverageOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2013Stifel NicolausInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2013Credit SuisseInitiated CoverageOutperform$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/28/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha